Copiktra (duvelisib) vs Velexbru (tirabrutinib hydrochloride)

Copiktra (duvelisib) vs Velexbru (tirabrutinib hydrochloride)

Copiktra (duvelisib) is a dual inhibitor of phosphoinositide 3-kinase (PI3K)-delta and PI3K-gamma, indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and follicular lymphoma. Velexbru (tirabrutinib hydrochloride), on the other hand, is a selective Bruton's tyrosine kinase (BTK) inhibitor, used primarily for the treatment of B-cell malignancies, such as mantle cell lymphoma, in Japan. When deciding between these two medications, a patient should consider factors such as the specific type of blood cancer they have, their previous treatments, potential side effects, and the mechanism of action of each drug as they may have different efficacy and safety profiles.

Difference between Copiktra and Velexbru

Metric Copiktra (duvelisib) Velexbru (tirabrutinib hydrochloride)
Generic name duvelisib tirabrutinib hydrochloride
Indications Chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and follicular lymphoma (FL) Relapsed or refractory primary central nervous system lymphoma (PCNSL)
Mechanism of action Phosphoinositide 3-kinase (PI3K) inhibitor Bruton's tyrosine kinase (BTK) inhibitor
Brand names Copiktra Velexbru
Administrative route Oral Oral
Side effects Diarrhea, neutropenia, rash, fatigue, pyrexia, cough, anemia, nausea, upper respiratory infection, pneumonia Neutropenia, thrombocytopenia, rash, diarrhea, muscle spasms, fatigue
Contraindications History of severe allergic reactions to duvelisib or any of its components None known specifically for tirabrutinib; general contraindications for BTK inhibitors apply
Drug class PI3K inhibitor BTK inhibitor
Manufacturer Secura Bio, Inc. Ono Pharmaceutical Co., Ltd.

Efficacy

Copiktra (Duvelisib) Efficacy in Treating Lymphoma

Copiktra (duvelisib) is an oral inhibitor of phosphoinositide 3-kinase (PI3K), and is specifically indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and follicular lymphoma (FL). The efficacy of Copiktra in treating these types of lymphoma has been demonstrated in clinical trials. In the DUO trial, a pivotal phase III study, duvelisib showed a significant improvement in progression-free survival (PFS) when compared to ofatumumab in patients with relapsed or refractory CLL/SLL. The median PFS was 13.3 months for patients treated with duvelisib, compared to 9.9 months for those receiving ofatumumab.

In the treatment of relapsed or refractory FL, the efficacy of Copiktra was evaluated in a single-arm, multicenter, open-label phase II study (DYNAMO). Patients who had received at least two prior systemic therapies showed a response rate of 42%, with a median duration of response of 10 months. These results indicate that Copiktra can be an effective treatment option for patients with FL who have exhausted other therapies.

Velexbru (Tirabrutinib Hydrochloride) Efficacy in Treating Lymphoma

Velexbru (tirabrutinib hydrochloride) is a selective Bruton's tyrosine kinase (BTK) inhibitor used in the treatment of various B-cell malignancies, including certain types of lymphoma. While Velexbru is not widely approved globally, it has been approved in Japan for the treatment of recurrent or refractory primary central nervous system lymphoma (PCNSL) and Waldenström's macroglobulinemia. In a multicenter, single-arm phase II study conducted in Japan, tirabrutinib demonstrated a high overall response rate (ORR) in patients with relapsed or refractory PCNSL. The ORR was reported to be approximately 67%, with a complete response rate of around 47%, indicating a significant potential for efficacy in this patient population.

It is important to note that the efficacy of these medications can vary based on individual patient factors, the specific subtype of lymphoma, and prior treatments received. Clinical trials continue to provide valuable information on the efficacy and safety profiles of these drugs, and further studies may expand their indications or provide more detailed insights into their use in different lymphoma subtypes. As with any medication, the use of Copiktra and Velexbru should be guided by a healthcare professional, and patients should be monitored for potential side effects and responses to therapy.

Regulatory Agency Approvals

Copiktra
  • European Medical Agency (EMA), European Union
  • Food and Drug Administration (FDA), USA
Velexbru
  • Pharmaceuticals and Medical Devices Agency (PMDA), Japan

Access Copiktra or Velexbru today

If Copiktra or Velexbru are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.

How it works

Make an enquiry

Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.

Breeze through the paperwork

We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.

Get a personalized quote

We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.

Receive your medicine

Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.

Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.

Let's talk

If you have any questions, call us or send us a message through WhatsApp or email:

Contact us
1